ArticleBritish journal of cancer2026

Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.

Michael E J López Mujica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.